epidemiolog
studi
show
risk
advers
cardiovascular
cv
outcom
stroke
myocardi
infarct
mi
heart
failur
hf
kidney
diseas
increas
progress
increas
blood
pressur
bp
hand
clinic
trial
demonstr
lower
bp
reduc
risk
antihypertens
medic
lower
bp
specif
drug
class
display
effect
beyond
bp
reduct
pleiotrop
effect
might
contribut
cardiovascular
risk
reduct
remodel
cardiovascular
structur
occur
respons
chang
bp
flow
also
modif
neurohormon
environ
renninangiotensinaldosteron
system
raa
exert
predomin
influenc
raa
major
regul
bp
addit
raa
role
vascular
respons
injuri
inflamm
chronic
raa
activ
angiotensin
ang
ii
aldosteron
lead
hypertens
perpetu
cascad
proinflammatori
prothrombot
atherogen
effect
associ
endorgan
damag
base
fact
sever
drug
develop
work
reduct
ang
ii
level
b
inhibit
ang
ii
type
receptor
c
blockad
aldosteron
receptor
renin
receptor
blockad
last
year
sever
clinic
trial
shown
benefit
drug
inhibit
raa
regard
bp
reduct
regress
cardiac
hypertrophi
prevent
kidney
damag
reduct
cardiovascular
morbid
reduct
hypertens
patient
besid
raa
blocker
qualiti
life
well
surviv
significantli
improv
patient
heart
failur
consequ
raa
current
main
therapeut
target
hypertens
treatment
aggress
bp
control
improv
outcom
patient
cv
diseas
stroke
nephropathi
might
benefici
effect
beyond
bp
lower
despit
reduct
cv
event
endorgan
damag
current
pharmacolog
strategi
cv
diseas
remain
primari
caus
death
world
american
annual
experi
progress
endstag
renal
diseas
esrd
popul
age
proport
affect
endorgan
damag
expect
grow
thu
relev
find
new
molecul
order
prevent
reduc
hypertens
well
patholog
cv
kidney
remodel
dysfunct
regard
activ
new
pathway
seem
counterbal
damag
due
raa
system
activ
review
current
experiment
evid
suggest
activ
pathway
protect
heart
vessel
possibl
kidney
advers
cardiovascular
remodel
hypertens
well
heart
failur
discoveri
angiotensinconvert
enzym
homologu
ad
complex
main
axi
raa
ang
ii
form
enzym
ace
play
major
role
grow
bodi
evid
point
possibl
promis
role
new
member
raa
oppos
effect
main
axi
dramat
chang
direct
cardiovascular
renal
research
view
pivot
role
enzym
regul
raa
newest
member
raa
share
approxim
similar
somat
form
ace
membranebound
carboxypeptidas
cellular
tissu
distribut
differ
ace
ace
express
endothelium
throughout
vasculatur
distribut
tissu
abund
express
heart
kidney
lung
small
intestin
testi
releas
circul
urin
shed
tumor
necrosi
factoralphaconvert
enzym
sheddas
respons
ectodomain
cleavag
shed
howev
normal
enzymat
activ
plasma
low
probabl
due
presenc
endogen
inhibitor
differ
ace
substrat
specif
function
form
ang
hydrolysi
ang
ii
b
ang
hydrolysi
ang
last
reaction
neglig
slow
sever
hundr
time
slower
ang
ii
hydrolysi
form
ang
vasodepressor
peptid
counterbalanc
vasopressor
effect
ang
ii
ang
subsequ
convert
ang
ace
neutral
endopeptidas
ang
may
convert
ang
ace
littl
evid
prove
exist
altern
hydrolysi
ang
ang
ii
tissu
drummer
et
al
prove
homogen
rat
kidney
lesser
extent
lung
convert
ang
ang
ii
due
aceindepend
aminopeptidas
nlike
carboxypeptidas
singh
et
al
confirm
pathway
ang
iang
ang
ii
realli
exist
glomeruli
streptozotocininduc
diabet
mellitu
rat
moreov
human
heart
tissu
main
product
ang
degrad
ang
ang
ii
gener
heart
chymas
ace
poorli
identifi
carboxypeptidas
although
data
prove
exist
altern
pathway
ang
ii
product
clinic
practic
still
block
ace
act
bradykinin
metabol
activ
inhibit
classic
ace
inhibitor
acei
thu
propos
activ
may
counterbal
effect
ace
prevent
accumul
ang
ii
tissu
ace
express
sever
biolog
substrat
consid
multifunct
enzym
act
monocarboxypeptidas
cleav
sever
nonraa
peptid
role
maintain
cardiovascular
homeostasi
bradykinin
member
kininogenkinin
system
bradykinin
form
bradkinin
action
carboxypeptidas
agonist
receptor
induc
tissu
injuri
bradykinin
vasodil
act
receptor
produc
precursor
kininogen
kallikrein
degrad
ace
degrad
bradykinin
ace
known
import
aspect
bp
regul
signific
degrad
bradykinin
remain
establish
addit
bradykinin
also
abl
degrad
peptid
propos
caus
vasoconstrict
known
regul
fluid
homeostasi
nonraa
peptid
kinetensin
dynorphin
neurotensin
long
time
ang
thought
devoid
biolog
activ
spite
earli
report
biolog
effect
import
ang
emphas
discoveri
ang
shown
releas
vasopressin
effect
ang
ii
neurohypophys
explant
action
oppos
ang
ii
name
vasodil
antitroph
effect
implic
vasodil
caus
bradykinin
sever
experi
suggest
import
interact
ang
prostaglandinbradykininnitr
oxid
system
ang
bind
ma
receptor
g
proteincoupl
receptor
mediat
vasodil
antiprolif
action
peptid
ma
receptor
heterooligomer
receptor
act
physiolog
antagonist
ang
ii
studi
reveal
ang
activ
endotheli
nitric
oxid
synthas
product
via
aktdepend
pathway
furthermor
tallant
et
al
show
presenc
antisens
probe
direct
ma
abolish
ang
induc
inhibit
protein
synthesi
cardiomyocyt
studi
also
reveal
ang
decreas
serumstimul
mitogenactiv
protein
kinas
activ
respons
block
dala
antagonist
ma
receptor
ang
ii
bind
high
affin
two
differ
receptor
member
seventransmembranedomain
gproteincoupl
receptor
gpcr
superfamili
gq
gi
respect
wherea
mediat
recogn
action
ang
ii
appear
oppos
part
effect
mediat
express
adult
tissu
smaller
amount
action
cell
signal
less
well
character
current
knowledg
suggest
stimul
mediat
vasodil
antigrowth
proapoptot
antiinflammatori
effect
henc
modul
cardiovascular
remodel
well
progress
atherosclerosi
stimul
activ
nocgmpdepend
pathway
occur
either
directli
indirectli
bradykinin
increas
endotheli
no
activ
express
activ
associ
phosphoryl
jnk
ptp
inhibitor
transcript
factor
dephosphoryl
link
antiprolif
antiinflammatori
effect
apoptosi
may
induc
relax
open
largeconduct
k
channel
bkca
neg
regul
vascular
rho
arho
kinas
pathway
also
enhanc
activ
tyrosin
phosphatas
vanadatesensit
phosphatas
littl
inform
literatur
respect
ang
probabl
peptid
initi
thought
activ
convers
ang
ang
gener
sever
carboxypeptidasetyp
enzym
includ
cathepsin
ang
present
healthi
volunt
patient
anim
treat
ace
inhibitor
acei
receptor
blocker
arb
circul
level
increas
patholog
condit
ie
earli
mi
howev
littl
current
known
ang
biolog
effect
initi
studi
show
incub
chines
hamster
ovari
cell
cho
ang
potenti
releas
arachidon
acid
bk
elev
also
resensit
receptor
desensit
bk
time
jackman
et
al
show
cho
cell
human
pulmonari
endotheli
cell
ang
significantli
activ
ang
enhanc
effect
aceresist
bradykinin
analogu
receptor
ang
also
augment
arachidon
acid
releas
kinin
studi
suggest
ang
may
endogen
inhibitor
ace
donoghu
et
al
propos
ang
competit
inhibitor
ace
itselfan
ace
substrat
condit
ace
inhibit
longterm
administr
acei
rat
ang
level
increas
plasma
kidney
increas
ang
steadyst
level
could
due
decreas
catabol
ang
ace
convers
increas
level
ang
could
due
increas
product
result
increas
avail
ang
substrat
result
indic
altern
pathway
ang
metabol
exist
pathway
may
amplifi
presenc
ace
inhibitor
determin
whether
ang
activ
per
se
becom
activ
convers
ang
chen
et
al
examin
metabol
ang
ang
ang
stabli
transfect
cho
cell
express
human
ace
human
bradykinin
receptor
coupl
green
fluoresc
protein
found
ang
hydrolyz
time
slower
ang
slower
ang
ang
inhibit
ace
resensit
desensit
receptor
independ
ace
inhibit
reflect
releas
arachidon
acid
mechan
involv
crosstalk
ace
receptor
conclud
ang
enhanc
bradykinin
activ
probabl
act
endogen
alloster
modifi
ace
receptor
complex
therefor
ace
inhibitor
block
convers
ang
enzym
like
still
releas
ang
metabolit
like
ang
enhanc
efficaci
acei
recent
et
al
use
radioligand
bind
assay
observ
ang
abl
bind
ang
ii
type
receptor
pki
demonstr
ang
ang
ii
affect
hypertrophi
receptor
blocker
alter
ang
iimedi
growth
block
effect
ang
despit
lower
affin
ang
ii
select
activ
ang
inconsist
current
pharmacolog
model
g
proteincoupl
receptor
signal
activ
inde
concept
function
select
individu
receptor
ligand
capac
select
stabil
conform
lead
distinct
signal
outcom
support
previou
studi
critic
amino
acid
mode
bind
ligand
investig
agonist
activ
particularli
sensit
peptid
modif
disrupt
contact
point
ang
ii
receptor
substitut
within
ang
ii
far
better
toler
exist
relax
conform
ang
ii
therefor
bind
multipl
indistinct
contact
point
sinc
ang
contain
entir
ang
ii
sequenc
plu
ctermin
histidin
observ
indic
differ
may
stabil
conform
abl
counteract
hypertroph
signal
cardiomyocyt
et
al
observ
function
competit
ang
ii
ang
conclud
ang
abl
antagon
ang
ii
signal
cardiomyocyt
select
via
highlight
ang
along
ang
make
part
counterregulatori
arm
ra
remain
determin
downstream
signal
effect
ang
preliminari
studi
indic
classic
pathway
via
pkc
transloc
activ
differ
ang
ii
ang
ang
stimul
cell
sinc
downstream
signal
unclear
present
futur
studi
requir
establish
mechan
crackow
et
al
first
test
gene
underli
blood
pressur
locu
x
chromosom
show
reduc
express
renal
saltsensit
sabra
hypertens
rat
compar
normotens
rat
spontan
hypertens
rat
shr
spontan
hypertens
strokepron
rat
shrsp
rat
show
reduc
renal
protein
level
compar
normotens
sabra
wistar
kyoto
wki
strain
two
group
confirm
find
show
lower
renal
mrna
protein
activ
shr
compar
wki
rat
howev
investig
unabl
detect
differ
renal
mrna
protein
activ
adult
hypertens
rat
normotens
control
rentzsch
et
al
assess
shrsp
display
reduc
mrna
protein
express
compar
control
anim
kidney
role
pathogenesi
hypertens
gener
transgen
rat
shrsp
genet
background
express
human
vascular
smooth
muscl
cell
use
promot
call
transgen
rat
vascular
smooth
muscl
cell
vsmc
express
human
confirm
rnase
protect
realtim
rtpcr
activ
assay
transgen
express
lead
significantli
increas
circul
level
ang
promin
product
mean
arteri
blood
pressur
reduc
compar
shrsp
rat
vasoconstrict
respons
intraarteri
administr
ang
ii
attenu
latter
effect
abolish
previou
administr
inhibitor
evalu
endotheli
function
vivo
endotheliumdepend
endotheliumindepend
agent
acetylcholin
sodium
nitroprussid
respect
appli
descend
thorac
aorta
blood
pressur
monitor
endotheli
function
turn
significantli
improv
rat
compar
shrsp
data
indic
vascular
overexpress
shrsp
reduc
hypertens
probabl
local
ang
ii
degrad
improv
endotheli
function
target
gene
therapi
strategi
hold
signific
potenti
translat
avail
fundament
research
therapeut
fact
initi
anim
experi
extrem
encourag
exampl
shr
viralmedi
overexpress
heart
decreas
high
bp
strategi
also
preserv
cardiac
function
well
left
ventricular
wall
motion
contractil
attenu
left
ventricular
wall
thin
induc
myocardi
infarct
overexpress
rostral
ventrolater
medulla
caus
signific
decreas
bp
heart
rate
hr
compar
acei
arb
target
follow
potenti
therapeut
advantag
first
degrad
ang
gener
ang
ang
ii
gener
ang
thu
target
would
produc
antihypertroph
peptid
ang
vasoprotectiveantiprolif
peptid
ang
would
also
influenc
vasoconstrictiveprolif
effect
aceang
axi
second
multifunct
enzym
mani
biolog
activ
substrat
third
unlik
arbacei
therapi
endogen
regul
ra
fourth
part
vasodilatoryantiprolif
axi
ra
fifth
although
treatment
acei
arb
indirectli
increas
express
direct
activ
enzym
could
result
better
outcom
cardiovascular
diseas
thu
activ
axi
may
novel
therapeut
strategi
hypertens
far
attent
focus
ang
oppos
pressor
prolif
profibrot
prothrombot
action
mediat
ang
ii
experiment
clinic
studi
demonstr
role
ang
axi
evolut
hypertens
regul
cardiovascular
renal
function
progress
cardiovascular
renal
diseas
includ
diabet
nephropathi
addit
evid
suggest
reduct
express
activ
vasodepressor
compon
may
critic
factor
mediat
progress
cardiovascular
renal
diseas
find
support
role
ang
axi
particular
put
role
aceang
receptor
counterregulatori
axi
within
ra
recent
altern
angiotensin
peptid
ang
shown
relev
biolog
function
ocaranza
et
al
observ
increas
activ
ang
plasma
level
mi
sham
rat
treat
enalapril
week
circul
ang
level
chang
phase
mi
figur
find
support
hypothesi
second
arm
ra
ang
instead
ang
could
act
counterregul
first
arm
ace
catalyz
format
ang
ii
besid
experiment
hypertens
doca
salt
model
normotens
sham
anim
rhoarhokinas
inhibit
signal
pathway
particip
patholog
cardiovascular
renal
remodel
also
blood
pressur
regul
fasudil
reduc
bp
increas
vascular
plasma
enzymat
activ
time
fasudil
reduc
ang
ii
increas
ang
plasma
level
figur
modif
observ
ang
level
despit
increas
level
rhoarhokinas
inhibit
thu
rhoarhokinas
inhibit
increas
eno
andor
reduc
ace
ang
ii
activ
ang
pathway
novel
effect
rhoarhokinas
inhibit
express
ang
level
might
addit
contribut
antihypertens
effect
rhoarhokinas
inhibitor
besid
result
strongli
suggest
experiment
model
hypertens
depend
ang
level
ace
ang
ii
level
therefor
second
raa
axi
ang
could
import
target
treatment
hypertens
vascular
wall
continu
expos
hemodynam
forc
lumin
pressur
shear
stress
chang
forc
either
physiolog
patholog
lead
function
andor
structur
alter
vascular
wall
acut
chang
hemodynam
forc
modifi
vessel
diamet
chronic
chang
hemodynam
forc
result
structur
alter
vessel
wall
indic
chang
wall
diamet
thick
addit
chang
vascular
structur
sole
determin
hemodynam
forc
also
inflammatori
respons
chang
extracellular
matrix
compon
structur
chang
medial
layer
vascular
wall
hypertens
term
eutroph
remodel
subsequ
translat
vascular
patholog
involv
inward
encroach
arteri
wall
therebi
reduc
diamet
lumen
sever
raa
compon
involv
neointim
format
vascular
endotheli
damag
particular
rakugi
et
al
observ
vascular
endotheli
damag
result
induct
vascular
ace
result
suggest
inhibit
vascular
ace
might
critic
prevent
restenosi
balloon
injuri
patient
previous
untreat
essenti
hypertens
eutroph
inward
remodel
appear
respond
antihypertens
medic
reduct
bp
drug
block
raa
acei
arb
calcium
channel
antagonist
abl
revers
eutroph
inward
remodel
protein
mrna
express
human
coronari
arteri
arteriol
vasa
vasorum
organ
recent
express
also
observ
larg
conduit
arteri
aorta
carotid
hr
local
preferenti
endotheli
cell
arteri
smooth
muscl
cell
smc
role
vascular
remodel
effect
neointima
format
yet
studi
ang
infus
ballooncathet
injuri
rat
carotid
arteri
reduc
neointima
format
effect
probabl
mediat
inhibit
vascular
smc
prolifer
hypertens
anim
model
mrna
protein
associ
immunoreact
ang
larg
conduit
arteri
shr
treatment
arb
induc
fivefold
increas
mrna
associ
signific
increas
aortic
ang
protein
express
effect
associ
decreas
aortic
medial
thick
suggest
may
protect
mechan
prevent
cardiovascular
event
hypertens
igas
et
al
show
protein
express
media
carotid
arteri
also
neointima
ballooninjur
carotid
arteri
shr
increas
protein
express
neointima
follow
exposur
rat
arb
compar
vehicl
associ
reduct
neointima
thick
result
lead
hypothesi
strong
correl
increas
protein
injur
carotid
arteri
shr
vascular
remodel
blockad
ang
ii
receptor
known
prothrombot
effect
ang
ii
antithrombot
action
ang
renovascular
hypertens
rat
thu
context
question
aris
whether
ang
effect
similar
ang
ii
ang
vivo
condit
kramkowski
et
al
describ
ang
enhanc
electr
stimul
thrombosi
rat
effect
abolish
antagonist
receptor
prothrombot
activ
ang
accompani
enhanc
ex
vivo
platelet
aggreg
vitro
ang
increas
platelet
aggreg
howev
point
paper
clarifi
first
thrombu
format
initi
electr
stimul
produc
arteri
injuri
unrel
clinic
situat
second
prothrombot
effect
ang
much
weaker
prothrombot
action
ang
ii
third
ang
slightli
increas
platelet
aggreg
vitro
condit
contrari
ocaranza
et
al
show
inhibit
rhoarhokinas
pathway
fasudil
gene
express
enzymat
ace
activ
plasma
level
ang
ii
reduc
figur
wherea
aortic
gene
express
activ
importantli
increas
simultan
plasma
level
ang
figur
mrna
eno
level
increas
aortic
overexpress
remodel
promot
protein
well
increas
aortic
nadph
oxidas
activ
product
reduc
consequ
direct
rhoarhokinas
inhibit
novel
effect
rhoarhokinas
inhibit
gene
express
enzymat
activ
ang
level
might
addit
contribut
benefit
hypertens
atherosclerosi
cardiovascular
renal
patholog
remodel
first
observ
concern
pharmacolog
ang
level
activ
normotens
hypertens
anim
one
interest
find
studi
figur
addit
experiment
hypertens
direct
rhoarhokinas
inhibit
also
normal
overexpress
gene
promot
vascular
remodel
interestingli
observ
chang
ang
level
present
fasudil
treatment
sham
doca
hypertens
rat
thu
vascular
remodel
could
depend
tissu
axi
ang
level
normotens
well
hypertens
rat
vessel
new
member
ra
detect
includ
ang
ma
vascular
function
activ
gener
ang
ang
ii
ang
found
endothelium
vascular
wall
immunohistochem
stain
show
abund
presenc
aortic
perivascular
adventiti
tissu
ang
bind
receptor
ma
endotheli
cell
oppos
ang
ii
action
mediat
vasodil
growthinhibit
antiinflammatori
respons
antiarrhythmogen
antithrombot
effect
nosderiv
product
activ
protein
tyrosin
phosphatas
reduc
mapk
activ
inhibit
nadph
oxidasederiv
gener
reactiv
oxygen
speci
ro
overexpress
vascular
wall
shr
associ
improv
endotheli
function
attenu
develop
hypertens
ang
ma
heterooligomer
therebi
inhibit
ang
ii
action
ma
axi
consid
counterregulatori
system
aceang
axi
vasculatur
although
evid
indic
ang
may
also
promot
fibrosi
inflamm
certain
condit
myocardi
injuri
respons
chronic
increas
hemodynam
load
cardiac
mass
increas
result
cardiomyocyt
hypertrophi
ventricular
wall
thicken
initi
chang
compensatori
mechan
help
maintain
eject
perform
heart
function
continu
hemodynam
overload
heart
becom
dilat
wall
thinner
result
geometri
contribut
systol
dysfunct
increas
wall
stress
cellular
level
cardiac
myocyt
increas
size
hypertrophi
rearrang
within
myocardi
matrix
cell
slippag
die
replac
fibrou
tissu
includ
fibroblast
collagen
chang
collect
refer
remodel
cardiac
remodel
consist
associ
impair
prognosi
patient
hypertens
mi
chronic
heart
failur
chf
despit
recent
advanc
understand
axi
function
role
heart
somewhat
controversi
crackow
et
al
origin
report
progress
reduct
lv
contractil
function
mice
without
signific
chang
fibrosi
left
ventricular
cardiac
myocyt
hypertrophi
mean
arteri
pressur
interestingli
wherea
plasma
tissu
level
ang
ii
increas
decreas
blood
pressur
observ
male
homozygot
mice
agematch
femal
male
convers
gurley
et
al
report
delet
enhanc
suscept
ang
iiinduc
hypertens
effect
cardiac
structur
function
huentelman
et
al
show
overexpress
protect
heart
ang
iiinduc
hypertrophi
fibrosi
recent
shr
hypertens
rat
et
al
use
lentiviralbas
gene
transfer
attenu
cardiac
fibrosi
hypertrophi
also
improv
lv
remodel
experiment
mi
final
yamamoto
et
al
report
delet
exacerb
pressur
overloadinduc
cardiac
dysfunct
remodel
associ
increas
intracardiac
ang
ii
level
activ
reason
discrep
seem
genet
background
mice
use
gene
delet
b
global
versu
tissuespecif
manipul
c
cardiac
respons
monitor
basal
pathophysiolog
condit
mi
ocaranza
et
al
observ
circul
lv
enzymat
activ
downregul
longterm
phase
lv
dysfunct
rat
b
effect
prevent
convent
ace
inhibitor
enalapril
c
plasma
ang
level
significantli
increas
mi
rat
shamoper
rat
treat
enalapril
week
circul
ang
level
chang
time
figur
base
find
propos
model
hf
ang
rather
ang
act
counterregul
ang
ii
recent
mi
rat
random
receiv
either
vehicl
acei
enalapril
arb
candesartan
week
ocaranza
et
al
observ
drug
prevent
lvh
increas
plasma
ang
level
sever
fold
ang
level
correl
neg
differ
lvh
marker
without
adjust
bp
reduct
effect
specif
neither
ang
ang
ii
bradykinin
correl
lvh
chronic
administr
ang
mi
rat
osmot
minipump
versu
vehicl
two
week
decreas
plasma
ang
ii
level
inhibit
ace
activ
also
prevent
cardiac
myocyt
hypertrophi
vitro
evid
incub
ang
ace
gener
ang
ang
neg
regul
hypertrophi
author
use
ang
receptor
blocker
investig
whether
ang
could
mediat
effect
ang
even
though
bioactiv
signific
increas
circul
ang
level
fold
compound
modifi
ang
depend
suppress
cardiac
myocyt
hypertrophi
induc
mi
vitro
experi
cardiac
myocyt
incub
norepinephrin
nm
ang
also
prevent
hypertrophi
effect
modifi
coincub
ang
understand
role
ang
compar
ang
cardiomyocyt
hypertrophi
et
al
studi
ang
effect
rat
neonat
rabbit
left
ventricular
cardiomyocyt
cardiomyocyt
hypertrophi
stimul
ang
ii
vasopressin
significantli
increas
cell
size
approxim
well
stimul
express
hypertrophi
gene
marker
atrial
natriuret
peptid
brain
natriuret
peptid
heavi
chain
myosin
light
chain
ang
ang
abl
block
hypertrophi
induc
either
agonist
effect
inhibit
captopril
support
previou
evid
ang
act
independ
ang
author
investig
receptor
signal
via
angiotensin
type
type
receptor
ma
antagonist
losartan
block
ang
iiinduc
vasopressininduc
hypertrophi
losartan
block
antihypertroph
effect
ang
ang
vasopressinstimul
cardiomyocyt
ma
antagonist
effici
block
antihypertroph
effect
ang
without
affect
ang
furthermor
ang
activ
also
inhibit
presenc
bradykinin
type
receptor
antagonist
without
affect
ang
moreov
et
al
observ
antagonist
abolish
antihypertroph
effect
ang
without
affect
ang
suggest
ang
signal
via
radioligand
bind
assay
demonstr
ang
abl
bind
pki
data
indic
axi
act
counterregul
ang
ii
effect
possibl
direct
novel
anticardiac
hypertrophi
axi
pharmacolog
treatment
base
ra
blockad
use
extens
treatment
hypertens
cv
remodel
howev
spite
success
pharmacolog
blockad
ra
preval
endorgan
damag
risen
steadili
last
sever
decad
observ
indic
novel
innov
approach
must
use
attempt
promot
effect
treatment
residu
cv
remodel
environ
axi
import
target
critic
tip
balanc
vasoconstrictiveprolif
vasodilatoryantiprolif
axi
ra
conceptu
axi
balanc
advers
effect
aceang
receptor
axi
figur
accumul
evid
suggest
express
ang
level
alter
diastol
systol
dysfunct
remodel
activ
axi
protect
heart
vessel
cardiovascular
remodel
conclus
noncanon
ra
arm
new
biolog
effector
ang
counterregul
classic
ra
